Skip to content

Mindfulness Training vs Recovery Support for Opioid Use, Craving, and Anxiety During Buprenorphine Treatment

Zev Schuman-Olivier, Hannah J. Goodman, Joseph Rosansky, A. K. Fredericksen, Javier Barria, Gareth Parry, Randi G. Sokol, Paula Gardiner, Benjamin Le Cook, Roger D Weiss

JAMA Network Open 2025 DOI: 10.1001/jamanetworkopen.2024.54950 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized clinical trial Peer reviewed
Sample size 196
Population Adults prescribed buprenorphine for opioid use disorder
Interventions Group-based mindfulness training group recovery support
Topics Anxiety Meditation
Key findings Mindfulness training was not superior to an active group recovery support intervention for reducing illicit opioid use. Both arms showed significant reductions in anxiety, and mindfulness produced a greater reduction in opioid craving than recovery support. The authors suggest mindfulness groups may have utility during buprenorphine treatment, especially for patients with residual craving.

Abstract

Key Points Question During buprenorphine treatment, does group-based mindfulness training reduce opioid use, craving, and anxiety compared with group recovery support? Findings In this randomized clinical trial including 196 adults prescribed buprenorphine for opioid use disorder, mindfulness was not superior at reducing illicit opioid use compared with an active group intervention with an evidence-based curriculum. Both arms experienced significantly reduced anxiety, and the reduction in opioid craving during mindfulness groups was greater than during recovery support groups, a significant difference. Meaning The findings of this study suggest that mindfulness groups may have utility during opioid use disorder treatment, especially for patients with residual opioid craving while prescribed buprenorphine.

Comparable studies

Other randomized controlled trials on anxiety, most cited first.

Study Year Design Participants
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Recovered recurrently depressed patients 2000 Randomized controlled trial n = 145
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety 2016 Randomized controlled trial n = 51
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression 2016 Double-blind, placebo-controlled, crossover trial n = 29
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Hallucinogen-naïve adults reporting regular participation in religious or spiritual... 2006 Double-blind study n = 36
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Adults with advanced-stage cancer and anxiety 2010 Double-blind, placebo-controlled study n = 12

Citations in the library

Cited by 7

and 2 more in the library

Cites 14

and 9 more in the library

Explore topics